tbuckley/cabot-search huggingface dataset:
The German Surgical Congress.
Authors: None W. W. K.
Journal: JAMA (1907)

Berlin, April 6, 1907. <h3>To the Editor:</h3> —The thirty-sixth annual meeting of the German Surgical Society has just come to an end. It has occurred to me that it might be of interest to some of your readers to learn something of its management. In many respects it is a decided improvement on the conduct of similar meetings with us, and we would do well to imitate them. Of the scientific proceedings I shall say nothing, as these you will get from others. The society has over 1,600 members and 76 new ones were added this year. It is, therefore, the largest, and I think it is fair to say also the most important surgical society in the world. Over 800 were in attendance. The meetings are always held in Easter week in the Langenbeckhaus, in Berlin. As the hall seats only 500 to 600, cards of admission have to
Klebsiella pneumoniae.
Authors: R Ebringer, D R Cawdell, P Cowling, A Ebringer
Journal: Annals of the Rheumatic Diseases (1978)

Klebsiella pneumoniaeSir, We are grateful for the opportunity of replying to the letters of Drs Brewerton and Warren and Dr Eastmond, Professors Cooke, and Wright (Annals, 37, 298)
Contemporary analysis of cystectomy complications.
Authors: Kevin Joseph Chua, Hiren V. Patel, Arnav Srivastava, Sai Krishnaraya Doppalapudi, Benjamin Lichtbroun, Sammy Elsamra, Eric A. Singer, Thomas L Jang, Saum Ghodoussipour
Journal: Journal of Clinical Oncology (2022)

473 Background: Radical cystectomy (RC) is a curative treatment for patients with invasive bladder cancer, but carries significant morbidity. Modern improvements in perioperative care have decreased length of stay (LOS) without effect on complication or readmission rates. Herein, we examine contemporary changes in complication rates of RC. Methods: The National Surgical Quality Improvement Program (NSQIP) database was queried for RC performed from 2006-2018 for nondisseminated bladder cancer identified by CPT, ICD-9 and 10 codes. Demographics and outcomes were studied across time periods: 2006-2011, 2012-2014 and 2015-2018. 30 day complications were classified as minor (urinary tract infection (UTI), superficial incisional surgical site infection (SSI), pneumonia, blood transfusion) or major (readmission, reoperation, sepsis/septic shock, deep vein thrombosis (DVT), stroke, reintubation, renal failure, myocardial infarction, pulmonary embolus (PE), dehiscence, cardiac arrest, deep incisional SSI, organ/space SSI, death). Results: We identified 11,351 RC performed during the study period. Baseline characteristics were similar across the different time periods. Mean length of stay (10.5, 9.8 and 8.6 days, respectively, p&lt;0.001) decreased over time while readmission (20.0, 21.3, and 21.0%, respectively) and mortality rates were stable (2.7, 1.7, 2.0%, respectively). There was a significant decrease in overall minor complications over time, including superficial SSIs and transfusions (Table). The rate of major complications decreased over time, though not statistically significantly. Deep SSIs and PEs significantly decreased, while sepsis rates remained stable and high over time (Table). Rates of UTI was stable over time (10.1%, 8.8%, 8.3%, respectively, p=0.11). Conclusions: An analysis of the contemporary era shows continued decrease in LOS after RC and a decrease in overall complications. This may reflect beneficial effects of changes in perioperative bladder cancer management such as increased use of neoadjuvant chemotherapy, enhanced recovery after surgery protocols and laparoscopic/robotic techniques. Further efforts to improve care must target infectious complications and readmissions.[Table: see text]
Regional trends in the cost of transurethral bladder tumor resection in the outpatient and physician office setting.
Authors: Fotios Kokkotos, Hannah Buser, Aimee An, Katherine Ferrara
Journal: Journal of Clinical Oncology (2022)

465 Background: TURBT is the standard surgical procedure for diagnosis, staging, and initial treatment of non-muscle invasive bladder cancer. This study aimed to identify current geographic trends associated with the use and cost of TURBT in Medicare beneficiaries. Methods: The Medicare Limited Data Set 100% sample of outpatient and 5% sample of carrier claims data from Q1 2019 to Q3 2020 was used for analysis. Patients who underwent TURBT were identified using CPT codes (55234, 52235, 52240). An analysis of variance (ANOVA) test was run comparing the difference in average claim payment amount, average beneficiary payment to physician, and average allowed charge amount between each region (West, Midwest, Northeast, and South). If the ANOVA test found a significant difference between regions, a t-test was run for all combinations of regions. Results: In the outpatient setting, we identified a total of 92,938 TURBT procedures between 2019 and Q3 2020, including 23,039 (Midwest), 19,890 (Northeast), 33,379 (South), and 16,630 (West). The average Medicare claim payment amount was $2,755 overall, $2,566 (Midwest), $2,866 (Northeast), $2,497 (South), and $3,092 (West). Beneficiaries paid an average of $605 in the Midwest, $673 in the Northeast, $572 in the South, and $697 in the West. The average total charge was $7,343, $7,189, $8,510, and $10,028 in the Midwest, Northeast, South, and West respectively. In the outpatient setting, there were no statistical differences for any cost related variables between the four regions. In the physician office setting, we identified 8,035 TURBT between 2019 and Q3 2020. There were 1,776, 1,577, 3,153, and 1,529 TURBT procedures in the Midwest, Northeast, South, and West, respectively. The average Medicare claim cost was $383 (Midwest), $372 (Northeast), $423 (South), and $417 (West). The average total allowed charges on the claim was $415 overall, and $392, $404, $430, and $432 in the Midwest, Northeast, South, and West, respectively. There was a significant statistical difference (p = 0.0154) for the average claim payment amount between the South and the Northeast. The two regions differed in average claim payment amount by $51 (95% CI: $15, $87). There was a significant difference in the average allowed charge amount between the South and Midwest (p = 0.019) and the West and Midwest (p = 0.016). Compared to the South, the Midwest had a lower average charge amount by $37 (95% CI: $9, $66). The West had a higher average charge amount than the Midwest by $40 (95% CI: $12, $68). Conclusions: This analysis demonstrated a significant difference in the cost of TURBT between regions in the physician office setting. The South had a significant higher claim payment amount than the Northeast. The allowed charge amount in the physician office setting for the South and the West were significantly higher than the Midwest.
Eye Injuries
Authors: Jane F. Desforges, Bradford J. Shingleton
Journal: New England Journal of Medicine (1991)

EYE injuries are common, preventable, and occasionally difficult to diagnose. Successful treatment depends on recognizing the full extent of the injury and promptly initiating appropriate care. In this article I review the evaluation of the injured eye and present guidelines for early identification and treatment of three common emergencies that threaten the vision — chemical burn, ruptured globe, and hyphema. I also include some comments about the prevention of eye injuries.Evaluation of Eye InjuriesA good history taking is as important in evaluating ophthalmic trauma as it is with any other medical problem. Each patient should be questioned about . . .
Interpreting Weight, Height, and Body Mass Index Percentiles in the US Centers for Disease Control and Prevention Growth Charts
Authors: David S. Freedman
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Normality sensing licenses local T cells for innate-like tissue surveillance
Authors: Duncan R. McKenzie, Rosie Hart, Nourdine Bah, Dmitry S. Ushakov, Miguel Muñoz-Ruiz, Regina Feederle, Adrian C. Hayday
Journal: Nature Immunology (2022)

The increasing implication of lymphocytes in general physiology and immune surveillance outside of infection poses the question of how their antigen receptors might be involved. Here, we show that macromolecular aggregates of intraepidermal γδ T cell antigen receptors (TCRs) in the mouse skin aligned with and depended on Skint1, a butyrophilin-like (BTNL) protein expressed by differentiated keratinocytes (KCs) at steady state. Interruption of TCR-mediated 'normality sensing' had no impact on γδ T cell numbers but altered their signature phenotype, while the epidermal barrier function was compromised. In addition to the regulation of steady-state physiology, normality sensing licensed intraepidermal T cells to respond rapidly to subsequent tissue perturbation by using innate tumor necrosis factor (TNF) superfamily receptors. Thus, interfering with Skint1-dependent interactions between local γδ T cells and KCs at steady state increased the susceptibility to ultraviolet B radiation (UVR)-induced DNA damage and inflammation, two cancer-disposing factors.
KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab + vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).
Authors: Neal D. Shore, Johann S. De Bono, Gero Kramer, Anthony M. Joshua, Xin Tong Li, Christian Heinrich Poehlein, Charles Schloss, Evan Y. Yu
Journal: Journal of Clinical Oncology (2022)

TPS204 Background: Treatment options are limited for patients with mCRPC that progresses after treatment with next-generation hormonal agents (NHAs)—such as enzalutamide and abiraterone acetate—or docetaxel. Approximately 20% of patients with adenocarcinoma mCRPC that progresses on androgen deprivation therapy develop t-NE mCRPC, which is associated with shortened overall survival (OS). The PD-1 inhibitor pembrolizumab showed antitumor activity as monotherapy in docetaxel-pretreated patients with adenocarcinoma mCRPC in the phase 2 KEYNOTE-199 trial. The T-cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitor vibostolimab showed antitumor activity when combined with pembrolizumab in pretreated patients with several tumor types in a phase 1 dose-escalation study. Combining PD-1 and TIGIT inhibition might have enhanced benefit in mCRPC, potentially both adenocarcinoma and t-NE. Methods: KEYNOTE-365 (NCT02861573) is a nonrandomized, open-label, multicohort, phase 1b/2 trial designed to evaluate the efficacy and safety of several pembrolizumab combination therapies in patients with mCRPC. Patients enrolled in cohort G will have confirmed adenocarcinoma of the prostate without small cell histology, per the investigator. Cohort H will enroll patients with t-NE (≥1% neuroendocrine cells in a recent biopsy specimen confirmed by central histology review). Each cohort will include patients who previously received docetaxel treatment for mCRPC. Prior treatment with ≤2 NHAs (for hormone-sensitive metastatic prostate cancer [mHSPC] or mCRPC) and 1 other chemotherapy for mCRPC is permitted. Enrollment in cohort H requires prostate cancer progression within 6 months of starting an NHA (for mHSPC or mCRPC) and within &lt; 6 cycles of docetaxel for mCRPC. Each cohort will enroll 40-100 patients with Eastern Cooperative Oncology Group performance status score 0 or 1. Both cohorts will receive MK-7684A, a coformulation of pembrolizumab 200 mg and vibostolimab 200 mg, IV every 3 weeks. Treatment will continue until disease progression, withdrawal of consent, or other discontinuation event. Primary end points are safety and tolerability, prostate-specific antigen (PSA) response rate, and objective response rate (ORR) per RECIST v1.1 by blinded independent central review (BICR). Secondary end points include time to PSA progression; ORR and radiographic progression-free survival per Prostate Cancer Working Group 3 (PCWG3)–modified RECIST v1.1 by BICR; duration of response and disease control rate per RECIST v1.1 and PCWG3-modified RECIST v1.1 by BICR; and OS. These cohorts of KEYNOTE-365 are enrolling in Australia, Germany, New Zealand, Spain, and the United States. Clinical trial information: NCT02861573.
Machine Learning in Arrhythmia and Electrophysiology
Authors: Natalia A. Trayanova, Dan M. Popescu, Julie K. Shade
Journal: Circulation Research (2021)

Machine learning (ML), a branch of artificial intelligence, where machines learn from big data, is at the crest of a technological wave of change sweeping society. Cardiovascular medicine is at the forefront of many ML applications, and there is a significant effort to bring them into mainstream clinical practice. In the field of cardiac electrophysiology, ML applications have also seen a rapid growth and popularity, particularly the use of ML in the automatic interpretation of ECGs, which has been extensively covered in the literature. Much lesser known are the other aspects of ML application in cardiac electrophysiology and arrhythmias, such as those in basic science research on arrhythmia mechanisms, both experimental and computational; in the development of better techniques for mapping of cardiac electrical function; and in translational research related to arrhythmia management. In the current review, we examine comprehensively such ML applications as they match the scope of this journal. The current review is organized in 3 parts. The first provides an overview of general ML principles and methodologies that will afford readers of the necessary information on the subject, serving as the foundation for inviting further ML applications in arrhythmia research. The basic information we provide can serve as a guide on how one might design and conduct an ML study. The second part is a review of arrhythmia and electrophysiology studies in which ML has been utilized, highlighting the broad potential of ML approaches. For each subject, we outline comprehensively the general topics, while reviewing some of the research advances utilizing ML under the subject. Finally, we discuss the main challenges and the perspectives for ML-driven cardiac electrophysiology and arrhythmia research.
Layer‐by‐Layer Assembled Smart Antibacterial Coatings via Mussel‐Inspired Polymerization and Dynamic Covalent Chemistry
Authors: Lei Yang, Lin Li, Haotian Li, Tianyou Wang, Xiancheng Ren, Yiyun Cheng, Yiwen Li, Quan Huang
Journal: Advanced Healthcare Materials (2022)

Bacterial colonization on the surface of medical implanted devices and bacterial infection-induced biofilm have been a lethal risk for patients of clinical treatment. While antibacterial coatings fabricated by layer-by-layer (LBL) assembly techniques have been well explored, the facile preparation of substrate-independent smart antibacterial coatings with on-demand antibiotics release profile and excellent antibacterial performance is still urgently needed. In this work, this goal is addressed by LBL assembly fabrication of robust antibacterial coatings using naturally occurring and commercially available building blocks (i.e., aminoglycosides, 5,6-dihydroxyindole, and formylphenylboronic acid) via the subsequentially performed mussel-inspired polymerization and dynamic covalent chemistries. The resulting antibacterial coatings on different substates all presente a dynamic feature (i.e., pH-responsive), on-demand antibiotics release properties, and highly effective antibacterial performance both in vitro and in vivo. It is envisioned that this work can expand the scope of LBL assembly technique toward the next generation of robust and universal antibacterial coating materials by using natural building blocks and readily available chemistries.
Salvage radiotherapy (SRT) in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer.
Authors: Markus Grabbert, Constantinos Zamboglou, Annika Josef, August Sigle, Simon K.B. Spohn, Anca L. Grosu, Christian Gratzke
Journal: Journal of Clinical Oncology (2022)

TPS212 Background: Goal of our study is to evaluate the efficacy and safety of immunotherapy in combination with standard salvage radiation therapy (SRT) in patients with biochemical recurrence (BCR) or prostate-specific antigen (PSA) persistence after radical prostatectomy (RP). The combination of immunotherapy (IO) with radiation therapy might provide a clinical benefit to patients with recurrent prostate cancer due to an induction of increased activity of the immune system against cancerous tissue (abscopal effect). Primary endpoint is complete biochemical response (PSA level below detection level) 60 weeks after start of trial treatment, which further defines prognosis of patients. Further explorative endpoints like radiographic progression-free survival, PSA-nadir level and time to PSA-nadir, time to initiation of subsequent therapy (secondary ADT or NHA) and quality of life as well as adverse events will be evaluated. Methods: The trial is as a phase II, open-label, single arm monocenter trial which evaluates the combination of pembrolizumab as study medication in combination with SRT. Pembrolizumab will be administered in a three-weekly scheme up to one year of treatment. A concomitant ADT is administered in high-risk patients only (PSA &gt; 0.7ng/ml or cN+ in imaging studies). All patients will be staged with PSMA PET-CT, if applicable. Additionally, blood and urine samples will be collected for correlative biomarker studies. A total of 49 patients are planned to be enrolled in this explorative study within 2 years. INCLUSION CRITERIA (excerpt) Histologically confirmed diagnosis of an adenocarcinoma of the prostate and a BCR or PSA persistence after RP. Histology of the RP specimen needs to fulfill the following criteria: adenocarcinoma of the prostate, Gleason score 7-10; pNX or pN0 or pN1 (max. 2 lymph nodes involved). Imaging within 30 days prior to study inclusion is mandatory (([68Ga] or [18F] PSMA PET-CT as standard imaging modality, alternatively CT abdomen and full-body bone scan). PSA value between ≥0.2 and ≤1.0 ng/ml, measured at least six weeks postoperatively. EXCLUSION CRITERIA (excerpt) Prior-therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137). Prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to registration (like neo-adjuvant androgen deprivation therapy (ADT), secondary hormone ablation or taxan-based chemotherapy). Distant metastases or suspicious lymph nodes outside the lower pelvis in imaging with PSMA PET-CT (patients with PET positive bone lesions that are morphologically not clearly suspicious of metastases and would not change clinical practice can be included). Clinical trial information: NCT04931979.
Selective targeting of skin pathobionts and inflammation with topically applied lactobacilli
Authors: Sarah Lebeer, Eline F.M. Oerlemans, Ingmar Claes, Tim Henkens, Lize Delanghe, Sander Wuyts, Irina Spacova, Marianne F.L. van den Broek, Ines Tuyaerts, Stijn Wittouck, Ilke De Boeck, Camille N. Allonsius, Filip Kiekens, Julien Lambert
Journal: Cell Reports Medicine (2022)

Tailored skin microbiome modulation approaches with probiotics are highly challenging. Here, we show that lactobacilli are underestimated members of the skin microbiota. We select specific strains of nomadic lactobacilli for their functional applicability on the skin and capacity to inhibit growth and inflammation by skin pathobionts. The strains are formulated as microcapsules for topical formulations and tested in patients with mild-to-moderate acne. The selected lactobacilli are able to reduce inflammatory lesions in a pilot and placebo-controlled study. Daily application for 8 weeks is associated with an in vivo temporary modulation of the microbiome, including a reduction in relative abundance of staphylococci and Cutibacterium acnes, and an increase in lactobacilli. The reduction in inflammatory lesions is still apparent 4 weeks after the topical application of the lactobacilli ended, indicating a possible additional immunomodulatory effect. This study shows that carefully selected and formulated lactobacilli are a viable therapeutic option for common acne lesions.
Council on Physical Therapy
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of Financial Strain With Mortality Among Older US Adults Recovering From an Acute Myocardial Infarction
Authors: Jason R. Falvey, Alexandra M. Hajduk, Christopher R. Keys, Sarwat I. Chaudhry
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2022 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal